THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Kenneth Berlin to Animals

This is a "connection" page, showing publications Kenneth Berlin has written about Animals.
Connection Strength

0.148
  1. Electrophysiologic actions of d,l-sotalol and GLG-V-13 in ischemically injured canine epicardium. J Cardiovasc Pharmacol. 2007 Sep; 50(3):304-13.
    View in: PubMed
    Score: 0.028
  2. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs. 2005 Oct; 23(5):417-28.
    View in: PubMed
    Score: 0.024
  3. Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships. J Med Chem. 1998 Sep 10; 41(19):3753-7.
    View in: PubMed
    Score: 0.015
  4. Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. J Med Chem. 1997 Oct 24; 40(22):3567-83.
    View in: PubMed
    Score: 0.014
  5. Chronic bile duct cannulation in laboratory rats. Lab Anim Sci. 1991 Oct; 41(5):486-92.
    View in: PubMed
    Score: 0.009
  6. Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther. 2009 May; 8(5):1227-38.
    View in: PubMed
    Score: 0.008
  7. The acute and subchronic toxicity of BRB-I-28, a novel class Ib antiarrhythmic agent, in CD-1 mice. Food Chem Toxicol. 2000 Sep; 38(9):817-23.
    View in: PubMed
    Score: 0.004
  8. Preliminary acute and subchronic toxicity studies of GLG-V-13, a novel class III antiarrhythmic agent, in mice. Arzneimittelforschung. 2000 Jan; 50(1):31-8.
    View in: PubMed
    Score: 0.004
  9. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J Med Chem. 1999 Oct 21; 42(21):4434-45.
    View in: PubMed
    Score: 0.004
  10. Class III electrophysiologic actions of imidazole-substituted diheterabicyclononanes in canine myocardium. J Pharmacol Exp Ther. 1997 Apr; 281(1):155-62.
    View in: PubMed
    Score: 0.003
  11. Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate. J Med Chem. 1996 Jun 21; 39(13):2559-70.
    View in: PubMed
    Score: 0.003
  12. Relationships among petroleum refining, water and sediment contamination, and fish health. J Toxicol Environ Health. 1995 Sep; 46(1):101-16.
    View in: PubMed
    Score: 0.003
  13. Pigmented subcutaneous spindle cell tumors in native gizzard shad (Dorosoma cepedianum). Carcinogenesis. 1995 Jul; 16(7):1529-35.
    View in: PubMed
    Score: 0.003
  14. Pharmacokinetics and plasma protein binding of the new potent class III antiarrhythmic agent 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3, 7-diazabicyclo[3.3.1]nonane dihydroperchlorate. Arzneimittelforschung. 1995 Jun; 45(6):670-5.
    View in: PubMed
    Score: 0.003
  15. Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent. Eur J Drug Metab Pharmacokinet. 1995 Apr-Jun; 20(2):151-61.
    View in: PubMed
    Score: 0.003
  16. Electrophysiological characterization of a novel class III antiarrhythmic agent, GLG-V-13 in the mammalian heart. Acta Physiol Hung. 1995; 83(1):13-30.
    View in: PubMed
    Score: 0.003
  17. Effects of novel antiarrhythmic agents, BRB-I-28 and its derivatives, on the heart mitochondrial respiratory chain and sarcoplasmic reticulum Ca(2+)-ATPase. Res Commun Mol Pathol Pharmacol. 1994 Aug; 85(2):193-208.
    View in: PubMed
    Score: 0.003
  18. Electrophysiologic actions of BRB-I-28 in ischemically injured canine myocardium. J Cardiovasc Pharmacol. 1993 Apr; 21(4):637-46.
    View in: PubMed
    Score: 0.003
  19. The comparative antiarrhythmic and proarrhythmic activity of a 3,7-diheterobicyclo[3.3.1]nonane, BRB-I-28, and lidocaine in the 1-4-day-old infarcted dog heart. Acta Physiol Hung. 1993; 81(3):289-99.
    View in: PubMed
    Score: 0.002
  20. High-performance liquid chromatographic determination of BRB-I-28, a novel antiarrhythmic agent, in dog plasma and urine. J Chromatogr. 1992 Dec 02; 583(2):274-9.
    View in: PubMed
    Score: 0.002
  21. Effects of BRB-I-28, a novel antiarrhythmic agent, and its derivatives on cardiac Na+,K(+)-ATPase, Mg(2+)-ATPase activities and contractile force. Res Commun Chem Pathol Pharmacol. 1992 Oct; 78(1):3-16.
    View in: PubMed
    Score: 0.002
  22. Electrophysiological actions of BRB-I-28 in canine myocardial tissues. J Pharmacol Exp Ther. 1991 Nov; 259(2):558-65.
    View in: PubMed
    Score: 0.002
  23. Novel heteroarotinoids: synthesis and biological activity. J Med Chem. 1991 Jan; 34(1):430-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES